ISPE Names John Bournas as President and CEO - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

ISPE Names John Bournas as President and CEO

ISPE—the International Society for Pharmaceutical Engineering announced it has hired John Bournas as president and CEO, succeeding Nancy Berg who announced plans to leave the society last fall. Bournas takes the helm at ISPE with extensive competencies in the healthcare association industry as well as significant international experience and brings to the Society a clear vision for the expansion of its global initiatives and business operations including leveraging technology to extend ISPE’s Membership and educational programs, ISPE reports in a press statement.

"I am certain that with John Bournas’ experience, ISPE is well positioned for continued success," said Damian Greene, Chairman of the ISPE Board of Directors. Greene added, "ISPE has achieved many major milestones during the past few years, including solidifying partnerships with global regulators and spearheading high profile initiatives such as the Drug Shortages Prevention Plan. Under John’s leadership, ISPE will continue to grow these partnerships and initiatives, building on the pharmaceutical industry knowledge and expertise that exists across our 20,000 strong global Membership."

John Bournas is currently CEO/executive director of the World Federation of Hemophilia (WFH) where he led growth of the group’s mission and awareness raising; executed successful corporate affairs partnerships and evolved the group’s digital delivery of educational programs and content. Prior to WFH, he was senior director of International Affairs at the American College of Cardiology; senior director, international at Cardinal Health; and was a former diplomat, with postings in Chile, Australia, and Japan.

"I am pleased to be joining ISPE at a critical time in the pharma and biopharma industry. With companies increasingly challenged to deliver innovative, high-quality medicines within more competitive constraints, Members look to ISPE’s leadership to stimulate dialog on global issues and to capture and share knowledge on implementation of new processes and methods with greater efficiency. I am eager to connect with Members and industry leaders in building collaborative plans that achieve ISPE’s mission and expand its global footprint", said Bournas in the statement.

Bournas earned his MBA at Macquarie University (Australia); MA, Political Science at Fordham University (New York) and BA, International Studies from Fairleigh Dickinson University (New Jersey).

John Bournas takes the helm at ISPE on Sept. 20 and will oversee ISPE’s Annual Meeting, Oct. 12–15, 2014 in Las Vegas, NV, which will coincide with the opening of the ISPE’s office in Washington, DC to establish a permanent executive presence there.

Source: ISPE


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here